| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
American Association for Cancer Research Annual Meeting 2016
|
Coburn, Cassandra
|
|
2016
|
17 |
6 |
p. 707-708
|
article
|
| 2 |
Analysis of prognosis in CLL: collaboration makes the difference
|
van Oers, Marinus H J
|
|
2016
|
17 |
6 |
p. 691-692
|
article
|
| 3 |
An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data
|
|
|
2016
|
17 |
6 |
p. 779-790
|
article
|
| 4 |
Antibody–drug conjugates for cancer therapy
|
Thomas, Anish
|
|
2016
|
17 |
6 |
p. e254-e262
|
article
|
| 5 |
Australia tax increases to price cigarettes out of reach
|
Kirby, Tony
|
|
2016
|
17 |
6 |
p. e228
|
article
|
| 6 |
Bortezomib improves survival in rare myeloma
|
Brower, Vicki
|
|
2016
|
17 |
6 |
p. e227
|
article
|
| 7 |
Cachexia in patients with cancer
|
Jafri, Syed H
|
|
2016
|
17 |
6 |
p. e220-e221
|
article
|
| 8 |
Cachexia in patients with cancer
|
Williams, Grant R
|
|
2016
|
17 |
6 |
p. e220
|
article
|
| 9 |
Cancer care in Bali
|
Kenyon, Georgina
|
|
2016
|
17 |
6 |
p. 710-712
|
article
|
| 10 |
Cancer in the aftermath of Nepal's earthquakes
|
Mishra, Shiva Raj
|
|
2016
|
17 |
6 |
p. 705-706
|
article
|
| 11 |
Cancer-related Wernicke-Korsakoff syndrome
|
Sechi, GianPietro
|
|
2016
|
17 |
6 |
p. e221-e222
|
article
|
| 12 |
Can short-term hormone therapy for rising PSA prolong survival?
|
D'Amico, Anthony V
|
|
2016
|
17 |
6 |
p. 687-688
|
article
|
| 13 |
Charities raise alarm over changes to UK Cancer Drugs Fund
|
Burki, Talha Khan
|
|
2016
|
17 |
6 |
p. e230
|
article
|
| 14 |
Complete lymph node dissection in melanoma
|
Ariyan, Charlotte
|
|
2016
|
17 |
6 |
p. 688-689
|
article
|
| 15 |
Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial
|
Leiter, Ulrike
|
|
2016
|
17 |
6 |
p. 757-767
|
article
|
| 16 |
Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus
|
Schmiegelow, Kjeld
|
|
2016
|
17 |
6 |
p. e231-e239
|
article
|
| 17 |
Correction to Lancet Oncol 2015; 16: 522
|
|
|
2016
|
17 |
6 |
p. e223
|
article
|
| 18 |
Correction to Lancet Oncol 2016; 17: 751
|
|
|
2016
|
17 |
6 |
p. e223
|
article
|
| 19 |
Correction to Lancet Oncol 2016; 17: 553
|
|
|
2016
|
17 |
6 |
p. e223
|
article
|
| 20 |
Correction to Lancet Oncol 2016; 17: 733
|
|
|
2016
|
17 |
6 |
p. e223
|
article
|
| 21 |
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|
Sartore-Bianchi, Andrea
|
|
2016
|
17 |
6 |
p. 738-746
|
article
|
| 22 |
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Vansteenkiste, Johan F
|
|
2016
|
17 |
6 |
p. 822-835
|
article
|
| 23 |
Encouraging results for PD-1 inhibition in gastric cancer
|
Smyth, Elizabeth C
|
|
2016
|
17 |
6 |
p. 682-683
|
article
|
| 24 |
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
|
Suker, Mustafa
|
|
2016
|
17 |
6 |
p. 801-810
|
article
|
| 25 |
Immediate androgen deprivation: for all or for some?
|
Leapman, Michael S
|
|
2016
|
17 |
6 |
p. 683-684
|
article
|
| 26 |
Ixazomib for multiple myeloma
|
Burki, Talha Khan
|
|
2016
|
17 |
6 |
p. e228
|
article
|
| 27 |
Joining forces for children with cancer in Latin America
|
Gonzalez-Ramella, Oscar
|
|
2016
|
17 |
6 |
p. 701-703
|
article
|
| 28 |
Knots and cancer
|
Ranscombe, Peter
|
|
2016
|
17 |
6 |
p. 713
|
article
|
| 29 |
Locally advanced pancreatic cancer: maybe not so local
|
O'Dwyer, Peter J
|
|
2016
|
17 |
6 |
p. 694-695
|
article
|
| 30 |
Maggie's podcast
|
Worley, Luke
|
|
2016
|
17 |
6 |
p. 714
|
article
|
| 31 |
New European guidance on patient-reported outcomes
|
Venkatesan, Priya
|
|
2016
|
17 |
6 |
p. e226
|
article
|
| 32 |
New risk loci for endometrial cancer identified
|
Burki, Talha Khan
|
|
2016
|
17 |
6 |
p. e229
|
article
|
| 33 |
NHS England misses cancer referral targets again
|
Burki, Talha Khan
|
|
2016
|
17 |
6 |
p. e224
|
article
|
| 34 |
Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review
|
Bentivegna, Enrica
|
|
2016
|
17 |
6 |
p. e240-e253
|
article
|
| 35 |
Pathological complete remission and long-term outcome—what do we know in 2016?
|
Gnant, Michael
|
|
2016
|
17 |
6 |
p. 693-694
|
article
|
| 36 |
PD-1 inhibition in advanced Merkel-cell carcinoma
|
Baker, Holly
|
|
2016
|
17 |
6 |
p. e225
|
article
|
| 37 |
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
|
Muro, Kei
|
|
2016
|
17 |
6 |
p. 717-726
|
article
|
| 38 |
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
|
Krop, Ian E
|
|
2016
|
17 |
6 |
p. 811-821
|
article
|
| 39 |
PI3K targeting in breast cancer: the end of the beginning?
|
Bachelot, Thomas
|
|
2016
|
17 |
6 |
p. 696-697
|
article
|
| 40 |
Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial
|
Bendixen, Morten
|
|
2016
|
17 |
6 |
p. 836-844
|
article
|
| 41 |
Post-operative survival of patients with lung cancer
|
Quoix, Elisabeth
|
|
2016
|
17 |
6 |
p. 697-698
|
article
|
| 42 |
Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial
|
Carrie, Christian
|
|
2016
|
17 |
6 |
p. 747-756
|
article
|
| 43 |
Severe sleep apnoea linked to melanoma risk
|
Tanday, Sanjay
|
|
2016
|
17 |
6 |
p. e229
|
article
|
| 44 |
SNP affects colorectal cancer outcomes with cetuximab
|
Brower, Vicki
|
|
2016
|
17 |
6 |
p. e230
|
article
|
| 45 |
Struggle, survival, and triumph: a comeback story
|
Gourd, Katherine
|
|
2016
|
17 |
6 |
p. 716
|
article
|
| 46 |
Student's death highlights gaps in China's health regulations
|
Ouyang, Yadan
|
|
2016
|
17 |
6 |
p. 709
|
article
|
| 47 |
Surveillance benefit for pancreatic cancer in high-risk individuals
|
Baker, Holly
|
|
2016
|
17 |
6 |
p. e227
|
article
|
| 48 |
Targeting HER2: precision oncology for colorectal cancer
|
Schmoll, Hans-Joachim
|
|
2016
|
17 |
6 |
p. 685-686
|
article
|
| 49 |
The added effect of depression on patients with cancer
|
Gunjur, Ashray
|
|
2016
|
17 |
6 |
p. e225
|
article
|
| 50 |
The Cancer Survivor's Garden Companion
|
Feetham, Nigel
|
|
2016
|
17 |
6 |
p. 714
|
article
|
| 51 |
The five Rs of chemotherapy
|
Tannock, Ian F
|
|
2016
|
17 |
6 |
p. 703-705
|
article
|
| 52 |
The smaller the better: a new concept in thoracic surgery?
|
Petrella, Francesco
|
|
2016
|
17 |
6 |
p. 699-700
|
article
|
| 53 |
Thyroid cancer subtype downgraded to non-cancer
|
Tanday, Sanjay
|
|
2016
|
17 |
6 |
p. e224
|
article
|
| 54 |
Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial
|
Duchesne, Gillian M
|
|
2016
|
17 |
6 |
p. 727-737
|
article
|
| 55 |
Training a new generation of surgical oncologists worldwide
|
Balch, Charles M
|
|
2016
|
17 |
6 |
p. 700-701
|
article
|
| 56 |
Trastuzumab cardiotoxicity in early-stage breast cancer
|
Burki, Talha Khan
|
|
2016
|
17 |
6 |
p. e226
|
article
|
| 57 |
Uniform definition of continuous-deep sedation
|
Morita, Tatsuya
|
|
2016
|
17 |
6 |
p. e222
|
article
|
| 58 |
Venetoclax: a new weapon to treat high-risk CLL
|
Rossi, Davide
|
|
2016
|
17 |
6 |
p. 690-691
|
article
|
| 59 |
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
|
Stilgenbauer, Stephan
|
|
2016
|
17 |
6 |
p. 768-778
|
article
|
| 60 |
Virtual surgery
|
Kirby, Tony
|
|
2016
|
17 |
6 |
p. 715
|
article
|
| 61 |
When is a carcinogen not a carcinogen?
|
The Lancet Oncology,
|
|
2016
|
17 |
6 |
p. 681
|
article
|
| 62 |
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
|
Gianni, Luca
|
|
2016
|
17 |
6 |
p. 791-800
|
article
|
Journal description